CD276 and neoplasm: In the absence of CD276 on tumor cells, plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA)—two recognized players in ECM remodeling—are affected, indicating that CD276 could be an upstream regulator for PAI-1 in tumor.